Biotechnology

Tango Therapeutics

Tango Therapeutics Stock Falls After Piper Sandler Downgrades Rating to Neutral

Tango Therapeutics released FY2026 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 578.09 K), actual EPS USD -0.317 (forecast USD -0.3141)

Tango Therapeutics Exceeds Earnings Expectations with Analysts Upgrading Price Targets

Tango Therapeutics released FY2025 Annual Earnings on March 5 Pre-Market (EST), Actual Revenue USD 62.38 M (Forecast USD 62.89 M), Actual EPS USD -0.8745 (Forecast USD -0.8918)

Tango Therapeutics released FY2025 Q4 earnings on March 5 Pre-Market EST, actual revenue USD 0 (forecast USD 500.4K), actual EPS USD -0.2944 (forecast USD -0.3209)

Tango Therapeutics Reports Q4 Net Loss of $38.7 Million and Advances Pancreatic Cancer Drug Trials

Tango Therapeutics to release FY2025 Q4 earnings on March 5, 2026, pre-market EST; forecast revenue USD 500.4 K, EPS USD -0.3209

Tango Therapeutics Inc. CFO Reports Disposal of Common Stock

B. Riley Securities Maintains Buy Rating on Tango Therapeutics

Tango Therapeutics released FY2025 9 Months Earnings on November 4 Pre-Market EST, with actual revenue of USD 62.38 M and EPS of USD -0.6435

Tango Therapeutics released FY2025 Q3 earnings on November 4 Pre-Market EST, actual revenue USD 53.81 M (forecast USD 41.24 M), actual EPS USD 0.13 (forecast USD -0.0137)

Tango Therapeutics Q3 EPS beats expectations

Tango Therapeutics Reports Q3 Net Income and Secures $225 Million Financing

Tango Therapeutics to Release FY2025 Q3 Earnings on November 4, Pre-Market EST; Forecast Revenue USD 41.24 M, EPS USD -0.0137

Lawson Assigns Strong Buy Rating to Tango Therapeutics

Third Rock Ventures IV Reports Sale of Tango Therapeutics Inc. Common Stock

Tango Therapeutics released FY2025 Q2 earnings on August 5 Pre-Market (EST), actual revenue USD 3.181 M (forecast USD 6.704 M), actual EPS USD -0.3514 (forecast USD -0.3457)

Tango Therapeutics released FY2025 Semi-Annual earnings on August 5 Pre-Market EST, actual revenue USD 8.573 M, actual EPS USD -0.7125

Tango Therapeutics to Release FY2025 Q2 Earnings on August 5, Pre-Market EST; Forecast Revenue USD 6.704 M, EPS USD -0.3457

Tango Therapeutics Launches New Strategy for Tumor Targeted Therapy

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

POET

WYFI

TNGX

BTBT

USAS

HTFL

FRMI

POET Tech(POET) fell 22.36%, with a trading turnover 1.8 Billion USD, and a year-to-date rose 152.3%. Rackspace Tech(RXT) fell 20.16%, with a trading turnover 232.6 Million USD, and a year-to-date rose 499.4%. Whitefiber(WYFI) fell 19.31%, with a trading turnover 83.7 Million USD, and a year-to-date rose 53.2%.

Top Gainers&Losers

POET Tech

Rackspace Tech

Whitefiber

York Space

Bit Digital

Dlocal Uruguay

Americas Gold and Silver

HeartFlow

Fermi

Top 10 US Stock Losers (5.15)

Tango Therapeutics shares are trading lower after Piper Sandler downgraded its rating on the stock from Overweight to Neutral and raised its price target from $16 to $24.

benzinga_article

Piper Sandler Cos

ALMS

Top analysts have downgraded several stocks, including Tango Therapeutics (from Overweight to Neutral), Viking Holdings (from Overweight to Equal-Weight), Alumis Inc (from Buy to Neutral), Aardvark Therapeutics (from Equal-Weight to Underweight), and A O Smith Corp (from Neutral to Underweight). Price targets were adjusted for each company. For detailed analyst ratings, visit the analyst ratings page.

Alumis

Viking

Aardvark Therapeutics

A.O Smith

This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Vanguard Group Inc. increased its holdings in Tango Therapeutics, Inc. by 33.6% in Q4, owning 6,750,977 shares valued at $59.81 million. Other institutional investors also raised their stakes. Insider Adam Crystal sold 54,345 shares, reducing ownership by 29.03%. Analysts have mixed ratings, with a consensus price target of $31.36. Tango's stock opened at $24.87, down 2.5%. The company reported earnings of ($0.32) per share, matching estimates.

Market Beat

Legal & General Group Plc

Vanguard Group Inc. Has $59.81 Million Holdings in Tango Therapeutics, Inc. $TNGX

Tango Therapeutics, Inc. has seen its stock's average price target raised from $23.9 to $26, indicating a potential upside of approximately 2%. Analysts' forecasts range from $16 to $40 per share. The consensus rating remains a "Buy" from 12 analysts, with 10 Buys and 2 Holds. This information is based on estimates from 10 analysts and reflects the latest market insights.

TradingView

Factset Research

Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $27.4, Implies 7% Upside

Earnings Watch

Tango Therapeutics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 0

Tango Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 0

Tango Therapeutics reported its Q1 2026 financial results, highlighting a cash position of $380 million, sufficient to fund operations into 2028. The company is advancing its vopimetostat drug in combination with RAS(ON) inhibitors for pancreatic cancer, with initial clinical data expected in 2026. The net loss for the quarter was $45.5 million, compared to $39.9 million in Q1 2025. Key leadership changes were announced, including new appointments to support late-stage development. Upcoming milestones include safety and efficacy data from ongoing trials in 2026.

StockTitan

Revolution Medicines

Erasca

Gilead Sciences

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | TNGX Stock News

Tango Therapeutics(TNGX.US)